NYSE:AORT Artivion (AORT) Stock Price, News & Analysis $25.11 -0.50 (-1.95%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$24.74▼$25.6150-Day Range$24.51▼$28.4652-Week Range$12.16▼$29.24Volume206,386 shsAverage Volume222,821 shsMarket Capitalization$1.05 billionP/E RatioN/ADividend YieldN/APrice Target$29.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Artivion alerts: Email Address Artivion MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside17.5% Upside$29.50 Price TargetShort InterestBearish8.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$626,518 Sold Last QuarterProj. Earnings Growth105.00%From $0.20 to $0.41 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.65 out of 5 starsMedical Sector618th out of 910 stocksSurgical & Medical Instruments Industry72nd out of 95 stocks 2.5 Analyst's Opinion Consensus RatingArtivion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArtivion has only been the subject of 4 research reports in the past 90 days.Read more about Artivion's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.06% of the float of Artivion has been sold short.Short Interest Ratio / Days to CoverArtivion has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.Change versus previous monthShort interest in Artivion has recently decreased by 3.06%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldArtivion does not currently pay a dividend.Dividend GrowthArtivion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AORT. Previous Next 2.2 News and Social Media Coverage News SentimentArtivion has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Artivion this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Artivion to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Artivion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $626,518.00 in company stock.Percentage Held by InsidersOnly 8.10% of the stock of Artivion is held by insiders.Percentage Held by Institutions86.37% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Artivion's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Artivion are expected to grow by 105.00% in the coming year, from $0.20 to $0.41 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Artivion is -104.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artivion is -104.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtivion has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Artivion's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. About Artivion Stock (NYSE:AORT)Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.Read More AORT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AORT Stock News HeadlinesAugust 30, 2024 | insidertrades.comArtivion, Inc. (NYSE:AORT) SVP Sells $84,083.85 in StockAugust 20, 2024 | insidertrades.comArtivion, Inc. (NYSE:AORT) VP Matthew A. Getz Sells 9,420 SharesSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 17, 2024 | insidertrades.comArtivion, Inc. (NYSE:AORT) SVP Jean F. Holloway Sells 2,383 SharesAugust 16, 2024 | insidertrades.comAnthony B. Semedo Sells 9,709 Shares of Artivion, Inc. (NYSE:AORT) StockSeptember 2, 2024 | finance.yahoo.comIs Now An Opportune Moment To Examine Artivion, Inc. (NYSE:AORT)?August 30, 2024 | msn.comShould You Invest in Artivion (AORT)?August 15, 2024 | finance.yahoo.comInsider Sale: Director Anthony Semedo Sells 9,709 Shares of Artivion Inc (AORT)September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 12, 2024 | msn.comArtivion, Inc. (NYSE:AORT) Q2 2024 Earnings Call TranscriptAugust 11, 2024 | nz.finance.yahoo.comTELA Bio, Inc. (TELA) latest stock news & headlines – Yahoo FinanceAugust 11, 2024 | finance.yahoo.comA Look At The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)August 11, 2024 | seekingalpha.comArtivion, Inc. (AORT) Q2 2024 Earnings Call TranscriptAugust 10, 2024 | seekingalpha.comArtivion, Inc. 2024 Q2 - Results - Earnings Call PresentationAugust 9, 2024 | markets.businessinsider.comAORT Stock Earnings: Artivion Beats EPS, Beats Revenue for Q2 2024August 8, 2024 | prnewswire.comArtivion Reports Second Quarter 2024 Financial ResultsAugust 5, 2024 | prnewswire.comArtivion to Participate in Upcoming Investor ConferencesJuly 25, 2024 | prnewswire.comArtivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial ResultsSee More Headlines Receive AORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artivion and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:AORT CUSIPN/A CIK784199 Webwww.cryolife.com Phone(770) 419-3355Fax770-426-0031Employees1,500Year FoundedN/APrice Target and Rating Average Stock Price Target$29.50 High Stock Price Target$30.00 Low Stock Price Target$28.00 Potential Upside/Downside+17.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.24) Trailing P/E RatioN/A Forward P/E Ratio125.55 P/E GrowthN/ANet Income$-30,690,000.00 Net Margins-2.22% Pretax Margin0.09% Return on Equity3.81% Return on Assets1.39% Debt Debt-to-Equity Ratio1.07 Current Ratio5.63 Quick Ratio4.04 Sales & Book Value Annual Sales$376.97 million Price / Sales2.78 Cash Flow$0.71 per share Price / Cash Flow35.32 Book Value$7.04 per share Price / Book3.57Miscellaneous Outstanding Shares41,700,000Free Float38,322,000Market Cap$1.05 billion OptionableOptionable Beta1.74 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. James Patrick Mackin (Age 57)Chairman, President & CEO Comp: $2.37MMs. Amy D. Horton CPA (Age 54)VP & Chief Accounting Officer Comp: $621.26kMs. Jean F. Holloway Esq. (Age 67)Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $841.43kMr. John E. Davis (Age 59)Senior VP & Chief Commercial Officer Comp: $802.02kMr. Matthew A. Getz (Age 55)VP of Human Resources & Chief Human Resources Officer Dr. Marshall S. Stanton M.D. (Age 67)Senior VP of Clinical Research & Chief Medical Officer Comp: $615.55kDr. Robert C. Thomson (Age 54)Vice President of Research & Development Mr. Florian TyrsVice President of Global OperationsMore ExecutivesKey CompetitorsPROCEPT BioRoboticsNASDAQ:PRCTAxonicsNASDAQ:AXNXEnvistaNYSE:NVSTTandem Diabetes CareNASDAQ:TNDMLivaNovaNASDAQ:LIVNView All CompetitorsInsiders & InstitutionsJean F HollowaySold 3,167 sharesTotal: $84,083.85 ($26.55/share)Perceptive Advisors LLCBought 124,725 shares on 8/16/2024Ownership: 6.700%Matthew A GetzSold 9,420 sharesTotal: $238,420.20 ($25.31/share)Millennium Management LLCSold 17,751 shares on 8/15/2024Ownership: 1.166%Jean F HollowaySold 2,383 sharesTotal: $61,386.08 ($25.76/share)View All Insider TransactionsView All Institutional Transactions AORT Stock Analysis - Frequently Asked Questions How have AORT shares performed this year? Artivion's stock was trading at $17.88 on January 1st, 2024. Since then, AORT stock has increased by 40.4% and is now trading at $25.11. View the best growth stocks for 2024 here. How were Artivion's earnings last quarter? Artivion, Inc. (NYSE:AORT) released its quarterly earnings results on Thursday, August, 8th. The company reported $0.07 earnings per share for the quarter, beating analysts' consensus estimates of $0.03 by $0.04. The firm earned $98.02 million during the quarter, compared to the consensus estimate of $97.70 million. Artivion had a negative net margin of 2.22% and a positive trailing twelve-month return on equity of 3.81%. Who are Artivion's major shareholders? Top institutional shareholders of Artivion include Perceptive Advisors LLC (6.70%), Dimensional Fund Advisors LP (4.05%), First Eagle Investment Management LLC (1.43%) and Millennium Management LLC (1.17%). Insiders that own company stock include James P Mackin, David Ashley Lee, Jean F Holloway, Marshall S Stanton, Andrew M Green, Rochelle L Maney, Dennis B Maier and Matthew A Getz. View institutional ownership trends. How do I buy shares of Artivion? Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:AORT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artivion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artivion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.